Anmelden Kostenlos registrieren

QSAM Biosciences Verschuldung / Eigenkapital

Was ist das Verschuldung / Eigenkapital von QSAM Biosciences?

Verschuldung / Eigenkapital von QSAM Biosciences, Inc. ist -3.34

Was ist die Definition von Verschuldung / Eigenkapital?



Die Verschuldung zu Eigenkapital ist ein Finanzverhältnis, das den relativen Anteil des Eigenkapitals und der Verschuldung angibt, die zur Finanzierung der Vermögenswerte eines Unternehmens verwendet werden.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Verschuldung / Eigenkapital von Unternehmen in Health Care Sektor auf OTC im Vergleich zu QSAM Biosciences

Was macht QSAM Biosciences?

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.

Unternehmen mit verschuldung / eigenkapital ähnlich QSAM Biosciences